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e 18, 2013.his study sought to determine how exercise inﬂuences penetrance of arrhythmogenic right ventricular dysplasia/
cardiomyopathy (ARVD/C) among patients with desmosomal mutations.Background Although animal models and anecdotal evidence suggest that exercise is a risk factor for ARVD/C, there have been
no systematic human studies.Methods Eighty-seven carriers (46 male; mean age, 44  18 years) were interviewed about regular physical activity from
10 years of age. The relationship of exercise with sustained ventricular arrhythmia (ventricular tachycardia/
ventricular ﬁbrillation [VT/VF]), stage C heart failure (HF), and meeting diagnostic criteria for ARVD/C (2010 Revised
Task Force Criteria [TFC]) was studied.Results Symptoms developed in endurance athletes (N ¼ 56) at a younger age (30.1  13.0 years vs. 40.6  21.1 years,
p ¼ 0.05); they were more likely to meet TFC at last follow-up (82% vs. 35%, p < 0.001) and have a lower lifetime
survival free of VT/VF (p ¼ 0.013) and HF (p ¼ 0.004). Compared with those who did the least exercise per year
(lowest quartile) before presentation, those in the second (odds ratio [OR]: 6.64, p ¼ 0.013), third (OR: 16.7,
p ¼ 0.001), and top (OR: 25.3, p < 0.0001) quartiles were increasingly likely to meet TFC. Among 61 individuals
who did not present with VT/VF, the 13 subjects experiencing a ﬁrst VT/VF event over a mean follow-up of
8.4  6.7 years were all endurance athletes (p ¼ 0.002). Survival from a ﬁrst VT/VF event was lowest among those
who exercised most (top quartile) both before (p ¼ 0.036) and after (p ¼ 0.005) clinical presentation. Among
individuals in the top quartile, a reduction in exercise decreased VT/VF risk (p ¼ 0.04).Conclusions Endurance exercise and frequent exercise increase the risk of VT/VF, HF, and ARVD/C in desmosomal mutation
carriers. These ﬁndings support exercise restriction for these patients. (J Am Coll Cardiol 2013;62:1290–7)
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3; revised manuscript received June 2, 2013,death (1,2). Incomplete penetrance and variable phenotypic
expression are characteristic of ARVD/C, suggesting
a potential role for environmental inﬂuences (3–5). Many
ARVD/C patients are highly athletic, and those who
participate in competitive athletics have been found to have
a 5-fold increased risk of sudden death compared with
nonathletes (6). It is currently recommended that ARVD/C
patients not participate in either competitive (7) or most
recreational (8) sports, but no recommendations have been
made for clinically unaffected mutation carriers.
Over the past decade, pathogenic ARVD/C-associated
mutations have been identiﬁed in 5 desmosomal genes
(PKP2, DSG2, DSP, DSC2, and JUP) (9–13). Cardiac
desmosomes are specialized adhesion junctions composed
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1291of a symmetrical group of proteinsdthe cadherins, armadillo
proteins, and plakinsdthat provide a mechanical connec-
tion between cardiac myocytes. Desmosomal mutations can
now be identiﬁed in as many as 60% of ARVD/C patients
(14,15). The appreciation that ARVD/C is in many cases
a “disease of the desmosome” suggests potential mechanisms
through which exercise, particularly endurance exercise,
could be a risk factor for ARVD/C (16,17).
Kirchhof et al. (18) showed that endurance exercise
accelerated the development of RV dysfunction and
arrhythmias in a plakoglobin-deﬁcient mouse model, but
there are no systematic human studies.
Clinical genetic testing for ARVD/C is now routinely
performed (19). Therefore, the clinician is now confronted
not only with ARVD/C patients seeking advice on physical
activity, but also with making recommendations for
a growing group of clinically unaffected mutation carriers.
Because familial ARVD/C is a clinically heterogeneous
disorder with incomplete penetrance and variable expres-
sivity (20,21), management of unaffected mutation carriers is
challenging as the individualized risk of the disease devel-
oping is uncertain. Discerning whether lifestyle choices
(exercise habits) can modify penetrance is critical. Therefore,
we developed a study of ARVD/C-associated desmosomal
mutation carriers to test the hypothesis that exercise inﬂu-
ences age-related penetrance, arrhythmic risk, and progres-
sion to heart failure in ARVD/C.Methods
Study population. The study population was recruited from
the Johns Hopkins ARVD/C Registry, which prospectively
enrolls ARVD/C patients and their family members. Partic-
ipants are contacted andmedical records are updated annually.
Registry participants who carried a single copy of a pathogenic
ARVD/C-associated desmosomal mutation, were 10 years of
age or older, and could speak English were invited to partic-
ipate in a detailed interview to document exercise history.
Parents were co-informants for children younger than 18 years
of age. All aspects of the study were approved by The Johns
Hopkins School of Medicine Institutional Review Board.
Genotype. Genotype was derived from direct sequencing of
the desmosomal genes PKP2, DSG2, DSC2, DSP, and JUP
through either our research (14,20) or commercially available
testing. Family members are screened only for mutations
identiﬁed in the proband. Individuals with digenic or
compound heterozygous mutations were excluded.
Clinical outcomes. Clinical and demographic data were
drawn from the Johns Hopkins ARVD/C Registry. Baseline
data included sex, date of birth, date and type of clinical
presentation, family history, and results of noninvasive
and invasive studies (12-lead electrocardiogram [ECG],
exercise testing, 24-h Holter monitoring, 2-dimensional
transthoracic echocardiography, cardiac magnetic resonance
imaging, signal averaged ECG, RV angiogram). Clinical
presentation was deﬁned as the ﬁrst medical visit fora cardiac symptom related to
ARVD/C. Primary outcomemea-
sures included ﬁrst sustained
ventricular arrhythmia (ventricular
tachycardia/ventricular ﬁbrillation
[VT/VF]), onset of stage C heart
failure (HF), and diagnosis of
ARVD/C at last follow-up (2010
Revised Task Force Criteria
[TFC]). First sustained ventricular
arrhythmia was a composite mea-
sure of the occurrence of sponta-
neous sustained VT, aborted
sudden cardiac death, or appro-
priate implantable cardioverter-
deﬁbrillator (ICD) intervention.
In patients without an ICD, VT/
VFoutcomewas adjudicated based
on reviewing ECGs and medical
records; in patients with an ICD, the device stored ECGs
were reviewed for appropriateness of ICD therapy. In patients
with multiple endpoints, the ﬁrst event was considered the
censoring event.HFwas deﬁned using theAmericanCollege of
Cardiology/American Heart Association heart failure staging
system (22), but required both evidence of structural heart
disease including RV abnormalities and symptoms directly
attributed to HF, as done previously (23). Heart failure was
adjudicated independently by 2 members of the study team
blinded to exercise history. The diagnosis of ARVD/C was
based on the presence of major and minor diagnostic criteria
according to the TFC (24).
Exercise interviews. Structured telephone or in-person
interviews were conducted by 3 genetic counselors and 1
physician. During the interview, we prompted participants
to list regular exercise done for leisure/recreation, work, and
transportation since 10 years of age. Two aspects of each
regularly performed exercise were collected: intensity and
duration. Intensity of each activity was rated as light,
moderate, or vigorous using language and deﬁnitions from
the Multi-Ethnic Study of Atherosclerosis Typical Week
Physical Activity Survey (25). To determine duration,
participants were asked between which ages they had
participated in each exercise activity. Then the participant
was asked on average how many months of the year, days of
the month, and hours per day that he or she did this activity
at each relevant intensity level. Responses were transcribed
on pre-prepared data collection sheets.
Exercise history analysis. In this study, we evaluated the
inﬂuence of 2 aspects of exercise history: 1) aerobic intensity,
deﬁned as participation in vigorous-intensity endurance
(aerobic) athletics; and 2) duration, deﬁned as annual hours
of all regular exercise. Endurance athletics were sports with
a high dynamic demand (>70% maximum O2), as deﬁned
by the 36th Bethesda Conference Classiﬁcation of Sports
(Task Force 8) (26), done for at least 50 h/year at vigorous
intensity. Vigorous intensity had been self-rated during the
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1292interview as described. Individuals meeting these criteria are
referred to as endurance athletes throughout this paper. For
exercise duration, average hours per year of all regular
exercise were calculated for each participant both before and
after clinical presentation.
Statistical analysis. Categorical variables are reported as
frequency (%) and compared between groups by the chi-
square or Fisher exact test. Continuous variables are
summarized as either mean  SD or median (interquartile
range [IQR]) and compared across groups using a Student
t or Mann-Whitney U test as appropriate. Median hours per
year of exercise before and after presentation were compared
by the Wilcoxon signed rank test. The likelihood of meeting
TFC was estimated using multivariate logistic regression.
Cumulative freedom from the composite arrhythmic
outcome and HF outcome were determined by the Kaplan-
Meier method. Differences in survival among groups were
evaluated with a log-rank test. A p value <0.05 was
considered signiﬁcant. SPSS version 20.0 statistical software
(SPSS Inc., Chicago, Illinois) was used.Results
Population. Of 134 mutation carriers from 68 families
invited to participate, 89 (66%) were interviewed. There was
no difference in response rate by sex or whether an indi-
vidual was a proband or family member. Two interviews
were excluded from analysis, one in which a minor and her
mother gave discordant responses and a second in which the
participant was unable to attend to interview questions due
to distress related to a change in her personal life.
The ﬁnal study population included 87 individuals (46
male) from 51 families with a single copy of a pathogenic
ARVD/C-associated desmosomal mutation (76 PKP2,
7 DSG2, 3 DSP, 1 DSC2) (Online Table 1). Age at inter-
view ranged from 11 to 88 years (mean, 44  18 years). Two
individuals were of Asian ancestry. The remaining subjects
were white. Approximately two thirds (57 of 87, 66%) met
TFC and 45% (39 of 87) had experienced at least 1 life-
threatening VT/VF episode at last clinical follow-up. In
10 (12%), HF had developed at last follow-up, and 2 (2%)
had undergone cardiac transplantation, both for VT.
Participants had 14 ﬁrst-degree relatives who had died of
ARVD/C-associated arrhythmias (13) or heart failure (1).
Additional clinical characteristics are shown in Table 1.
Exercise history. Overall, 56 of 87 (64%) participants had
been endurance athletes. The most common endurance
sports were long- and middle-distance running (37 of 56,
66%), basketball (27 of 56, 48%), soccer (14 of 56, 25%), and
competitive swimming (8 of 56, 14%). Other qualifying
sports included distance cycling (5), lacrosse/ﬁeld hockey (5),
tennis/squash (4), rowing (1), and cross-country skiing (1).
Some endurance athletes competed in multiple endurance
sports. The median age at starting a ﬁrst endurance sport was
14 years (range: 10 to 45 years; IQR: 10 to 18 years). Males
were not signiﬁcantly more likely to have been enduranceathletes. There was no signiﬁcant difference in the age at
interview between endurance athletes and nonathletes.
Interviewees participated in a median of 284 h/year
(range: 0 to 2,657 h/year; IQR: 135 to 509 h/year) of regular
exercise of all types before presentation and a median 155 h/
year (range: 0 to 1,658 h/year; IQR: 17 to 314 h/year)
afterward (p < 0.001). Most individuals (61 of 87, 70%)
decreased exercise after presentation, with no difference
between athletes and nonathletes. Endurance athletes did
more annual exercise before presentation (median: 404 h/
year; IQR: 210 to 684 h/year) than nonathletes (median: 135
h/year; IQR: 38 to 243 h/year) (p < 0.001). There was no
signiﬁcant difference in annual exercise after clinical
presentation between endurance athletes and nonathletes.
Inﬂuence of participation in endurance athletics on
clinical course. As shown in Table 1, mutation carriers who
were endurance athletes had a different presentation and
clinical course than nonathletes. Endurance athletes weremore
likely to be probands (50% athletes vs. 26% nonathletes,
p ¼ 0.028) and to have cardiac symptoms (VT/VF, syncope,
presyncope, palpitations, or chest pain) at presentation (68%
athletes vs. 29% nonathletes, p¼ 0.001) and during follow-up
(75% athletes years vs. 32% nonathletes, p < 0.001). Symp-
toms developed in endurance athletes at a younger age than
nonathletes (30.1 13.0 years vs. 40.6 21.1 years, p¼ 0.05).
Lifetime arrhythmic riskwashigher among endurance athletes.
Overall, 31 endurance athletes (55%) had experienced at least 1
sustained VT/VF at last follow-up compared with 8 (26%)
nonathletes (p ¼ 0.008) (Table 1). As shown in Figure 1A,
cumulative lifetime event-free survival from VT/VF was
signiﬁcantly lower in endurance athletes (p ¼ 0.013).
ARVD/C diagnosis. We evaluated the inﬂuence of both
participation in endurance athletics and average annual dura-
tion of all exercise on likelihood of meeting diagnostic criteria
(TFC) at last follow-up. Endurance athletes were more likely
to meet both overall TFC (82% vs. 35%, p < 0.001) (Fig. 2)
and criteria for each of the domains of the TFC (structural
abnormality/dysfunction, repolarization abnormalities, depo-
larization abnormalities, arrhythmias) except family history/
genetics (Table 1). The absence of a relationship with genetics
is consistent with the entry criteria for this study requiring that
all subjects have a pathogenic desmosomal mutation.
The amount of annual exercise was also positively corre-
lated with an increasing likelihood of meeting TFC at last
follow-up. Among those who participated in the fewest
(lowest quartile) hours per year of exercise at presentation, 6 of
21 (29%) met TFC compared with 14 (64%) in the second
quartile, 22 (82%) in the third quartile, and 19 (86%) among
those in the top quartile (p< 0.001) (Fig. 2). Controlling for
sex and age at last clinical follow-up, compared with those
who did the least (lowest quartile) exercise, those in the
second (odds ratio [OR]: 6.64; 95% conﬁdence interval
[CI]: 1.49 to 29.5, p¼ 0.013), third (OR: 16.7; 95%CI: 3.21
to 86.9, p¼ 0.001), and top (OR: 25.3; 95% CI: 4.21 to 153,
p < 0.0001) quartiles of exercise per year before presentation
were increasingly likely to meet TFC at the last follow-up.
Table 1 Association Between Clinical Characteristics and Participation in Endurance Athletics
Overall
(N ¼ 87)
Endurance Athlete
(n ¼ 56)
Not Endurance Athlete
(n ¼ 31) p Value
Male 46 (53) 32 (57) 14 (45) NS
Proband 36 (41) 28 (50) 8 (26) 0.028
Age at interview, yrs 44  18 42  15 45  22 NS
Presentation
Age at clinical presentation, yrs 35  17 32  14 38  20 NS
Type of presentation
Symptomatic presentation 44 (51) 36 (64) 8 (26) 0.002
Resuscitated SCD 3 (3) 2(4) 1 (3)
Asymptomatic 40 (46) 18 (45) 22 (71)
Sustained VT/VF at presentation 26 (30) 18 (32) 8 (26) NS
Stage C HF at presentation 0 (0) 0(0) 0(0) NS
Age at ﬁrst symptom, yrs 32  15 30  13 41  21 0.05
Task Force Criteria at LFU, yes 56 (64) 46 (82) 11 (35) <0.001
Structural alterations 30 (35) major
10 (12) minor
24 (44) major
8 (15) minor
6 (20) major
2 (7) minor
0.021
Repolarization abnormalities* 43 (50) major
15 (17) minor
34 (62) major
12 (22) minor
9 (29) major
3 (10) minor
<0.001
Depolarization abnormalities* 5 (6) major
35 (41) minor
5 (9) major
28 (51) minor
0 (0) major
7 (23) minor
0.003
Arrhythmiasy 17 (21) major
30 (36) minor
13 (24) major
24 (44) minor
4 (14) major
6 (21) minor
0.011
Family history/genetics 87 (100) major 56 (100) major 31 (100) major 1.000
VT/VF at LFU (yes) 39 (45) 31 (55) 8 (26) 0.008
Type of arrhythmic event
Sustained VT 29 (74) 22 (71) 7 (88) NS
Aborted SCD/resuscitated SCD 3 (18) 2 (6) 1 (12)
Appropriate ICD therapy 7 (8) 7 (23) 0 (0)
Activity at ﬁrst VT/VF
Exercise 25 (64) 21 (68) 4 (50) NS
Daily activity 10 (26) 6 (19) 4 (50)
At rest 4 (10) 4 (13) 0 (0)
Age ﬁrst VT/VF, yrs 33  12 32  11 37  16 NS
Stage C heart failure at LFU (yes) 10 (12) 10 (18) 0 (0) 0.012
Transplant at LFU 2 (2) 2 (4) 0 (0) NS
Values are n (%) or mean  SD. *One 11-year-old participant had no electrocardiogram available for review. Therefore, only 86 individuals were
characterized for repolarization and depolarization abnormalities. yThree individuals had Holter monitoring performed, noting that premature
ventricular complexes were present, but no count was provided, so these individuals were not included in the arrhythmias category.
HF ¼ heart failure; LFU ¼ last clinical follow-up; SCD ¼ sudden cardiac death; VT/VF ¼ composite measure of the occurrence of spontaneous
sustained ventricular tachycardia/ventricular ﬁbrillation, aborted SCD, SCD, or appropriate implantable cardioverter-deﬁbrillator intervention for
a ventricular arrhythmia.
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1293Heart failure. We also evaluated the inﬂuence of both
intensity (participation in endurance athletics) and duration
(hours per year of all exercise) on the incidence ofHF.None of
our population hadHF at presentation; HF developed in 12%
during follow-up.Mean age at onset of HF was 42 18 years
(range: 19 to 74 years). HF developed only in endurance
athletes (18% vs. 0%, p ¼ 0.012). As shown in Figure 1B,
cumulative lifetime survival free from HF onset was signiﬁ-
cantly lower among endurance athletes (p ¼ 0.004).
HFwasmore likely to develop in participants who didmore
average annual exercise before presentation (8 of 44, 18%more
hours of exercise vs. 2 of 43, 5% fewer hours, p¼ 0.048).Hours
of annual exercise after presentation, sex, and age at presen-
tation had no association with the development of HF.
Arrhythmic outcome. The relationship between exercise
and development of a ﬁrst sustained ventricular arrhythmia(VT/VF) during follow-up was evaluated in the subset of
61 subjects (70%) who did not present clinically with VT/VF.
Thirty-eight of these 61 were endurance athletes (62%). This
group of 61 decreased exercise from a median 242 h/year
before presentation (range: 0 to 2,657 h/year; IQR: 119 to
516 h/year) to 212 h/year (range: 0 to 1,658 h/year; IQR: 16
to 425 h/year) afterward (p ¼ 0.021).
Over a mean follow-up of 8.4  6.7 years, 13 of these
61 subjects (21%) experienced a ﬁrst VT/VF, including a resus-
citated sudden cardiac arrest in 1 individual.Themeanage atﬁrst
VT/VF was 32.3 7.8 years (range: 22 to 45 years). The mean
VT cycle length was 282 ms (range: 240 to 394 ms). Events
disproportionately occurred in younger individuals (p¼ 0.018).
There was no difference by sex. Thirteen of the 38 endurance
athletes (34%) experienced a ﬁrst VT/VF during follow-up
compared with none of the 23 nonathletes (0%) (p¼ 0.002).
Figure 1 Cumulative Lifetime Survival Free from Sustained Ventricular Arrhythmia and Class C Heart Failure
Cumulative lifetime survival free of sustained ventricular arrhythmias (A) and stage C heart failure (B) stratiﬁed by participation in endurance athletics. Event-free survival from
sustained arrhythmias and stage C heart failure is signiﬁcantly lower among endurance athletes. HF ¼ heart failure; VT/VF ¼ ventricular tachycardia/ventricular ﬁbrillation
(sustained ventricular arrhythmia).
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1294Duration of annual exercise (all types of regular exercise)
both before and after clinical presentation was also associated
with a ﬁrst VT/VF. In those who did the most (top quartile)
hours of exercise annually before presentation (>516 h/year),
VT/VFwas disproportionately likely to develop (7 of 16 [43%]
top quartile vs. 6 of 45 [13%] bottom 3 quartiles, p ¼ 0.01).
VT/VFwas also more likely to develop in patients who did theFigure 2 Likelihood of ARVD/C Diagnosis Is Associated With Exerci
Likelihood of meeting arrhythmogenic right ventricular dysplasia/cardiomyopathy (ARVD/C
exercise (p < 0.001) and participation in endurance athletics (p < 0.001). TFC ¼ 2010most exercise (>425 h/year) after clinical presentation during
follow-up (8 of 15, 53% top quartile vs. 5 of 46, 11% in bottom
3 quartiles, p < 0.001). Overall, event-free survival free from
a ﬁrst VT/VF during follow-up was signiﬁcantly lower among
endurance athletes (Fig. 3A) (p ¼ 0.012) and among those
who exercised most before (Fig. 3B) (p ¼ 0.036) and after
(Fig. 3C) (p ¼ 0.005) clinical presentation.se History
) diagnostic criteria at last follow-up is associated with increasing hours per year of
Task Force Criteria.
Figure 3
Cumulative Survival Free from a First Sustained
Ventricular Arrhythmia During Follow-up
Among 61 subjects who did not present clinically with a sustained ventricular
arrhythmia, survival free from a ﬁrst sustained ventricular arrhythmia during follow-up
was signiﬁcantly lower among endurance athletes (A) and those doing the most (top
quartile hours per year) exercise before (B) and after (C) clinical presentation. VT/
VF¼ ventricular tachycardia/ventricular ﬁbrillation (sustained ventricular arrhythmia).
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1295Inﬂuence of change in exercise duration on arrhythmic
outcome. The impact of changing duration of annual
exercise on the likelihood of developing a ﬁrst VT/VF was
also evaluated in these 61 participants. We examined
whether patients were in the top quartile for hours of
annual exercise (all types/intensity levels) before and after
presentation. As shown in Figure 4, ﬁrst VT/VF events
occurred disproportionately more frequently in individuals
who did the most (top quartile) exercise both before and
after clinical presentation (p ¼ 0.007). Among 16 indi-
viduals who did the most (top quartile) exercise before
presentation, 6 of 8 (75%) who continued do top quartile
exercise after presentation had a ﬁrst VT/VF in follow-up
compared with only 1 of 8 (12%) who decreased exercise
after presentation (p ¼ 0.04) (Fig. 4). Among 45 indi-
viduals who were in the lowest 3 quartiles of hours of
exercise before clinical presentation, in 4 of 38 (10%) who
continued lower levels of exercise, a ﬁrst arrhythmia
developed compared with 2 of 7 (29%) who increased
exercise to the top quartile level (p ¼ NS).Discussion
Main ﬁndings. The results of this study reveal for the ﬁrst
time in humans that the amount and intensity of exercise
increases the likelihood of diagnosis, ventricular arrhythmias,
and the development of HF among ARVD/C desmosomal
mutation carriers. Furthermore, the results suggest that reduc-
ing exercise duration may alter the clinical course of ARVD/C.
Relationship between exercise and ARVD/C. During
the 30 years since publication of the ﬁrst major reports
describing ARVD/C (1,27), threads of evidence have
emerged suggesting that exercise inﬂuences both the devel-
opment of ARVD/C and its associated arrhythmic risk. One
of the ﬁrst to highlight this important link was a study of
sudden cardiac death in the Veneto region of Italy, which
found that young athletes had a 5-fold higher risk of dying
of ARVD/C compared with nonathletes (6). Consistent
with this observation, implementation of a pre-participation
screening program resulted in a sharp decline in such deaths
(28). The next major line of evidence supporting a link
between ARVD/C and exercise was the landmark discovery
that a mutation in the desmosomal protein plakoglobin
(JUP) caused an unusual variant of ARVD/C (12) and
subsequent discovery of ARVD/C-associated mutations in
other desmosomal genes (9–11,13). The cardiac desmosome
provides a mechanical connection between myocytes. A
third line of evidence concerns the body of research on the
differential response of the right ventricle and left ventricle
to exercise (29,30). Compared with rest, RV wall stress at
peak exercise in athletes increases by 170% compared with
only a 23% increase in left ventricular wall stress. Intense
endurance exercise causes acute dysfunction of the right
ventricle, but not the left ventricle (30). The right ventricle
of individuals with desmosomal mutations may be particu-
larly vulnerable to pathological remodeling in response to
Figure 4
Change in Exercise After Clinical Presentation Inﬂuences Likelihood of the Development of a First Sustained
Ventricular Arrhythmia
Among 61 subjects who did not present clinically with a sustained ventricular arrhythmia, in those who did the most (top quartile) exercise both before and after clinical
presentation, a sustained ventricular arrhythmia during follow-up (p ¼ 0.007) was most likely to develop. Among those doing the most (top quartile) exercise before presen-
tation, in those who continued to do top quartile exercise a ﬁrst sustained ventricular arrhythmia was more likely to develop than in those who reduced exercise (p ¼ 0.04).
VT/VF ¼ ventricular tachycardia/ventricular ﬁbrillation (sustained ventricular arrhythmia).
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1296exercise. In these patients, endurance exercise may facilitate
myocyte uncoupling at defective desmosomes leading to
inﬂammation, ﬁbrosis, adipocytosis, and direct impairment
of electrical coupling (16). This sets the stage for arrhyth-
mias, worsening structural involvement, and HF. A ﬁnal
thread of evidence supporting a causative link between
exercise and ARVD/C was established by Kirchof et al. (18)
using a plakoglobin-deﬁcient mouse model. In this model,
endurance exercise accelerated the development of RV
dysfunction and ventricular arrhythmias.
Impact of exercise on the clinical course of ARVD/
C-associated mutation carriers. This study tested the
hypothesis that exercise is an important environmental factor
in the development of ARVD/C among mutation carriers
and inﬂuences outcomes of ARVD/C patients. The foun-
dational work described earlier provided circumstantial
evidence that exercise inﬂuences penetrance, arrhythmic risk,
and progression to HF, but there have been no systematic
studies in humans. Furthermore, the seminal work by
Corrado et al. (6) assumed that “sports per se is not a cause
of the increased mortality, rather, it acts as a trigger for
cardiac arrest in the presence of underlying cardiovascular
disease.” and therefore that the incidence of ARVD/C is
the same in the athletic and nonathletic populations. With
new appreciation of the pathogenesis of ARVD/C and the
incomplete penetrance of disease, it is likely instead that the
underlying proportion of athletes with disease may be
substantially greater. Furthermore, the Corrado et al. study
relied on autopsy cases, providing limited guidance to
physicians treating mildly affected patients and unaffected
mutation carriers. A strength of our study is the inclusion
of not just ARVD/C patients, but also their at-risk relatives
with desmosomal mutations. Furthermore, we found
endurance athletes with desmosomal mutations not onlywere more likely be at risk of life-threatening arrhythmias,
but also at increased risk of the development of the full
ARVD/C phenotype and HF. We also examined for the
ﬁrst time the relationship between quantity of total exercise
and outcomes of patients. We found that the duration of
annual exercise is positively associated with increasing risk of
meeting diagnostic criteria, of a ﬁrst sustained arrhythmia,
and of HF. Furthermore, among individuals doing the most
average annual exercise at presentation, reducing exercise
duration appeared to reduce arrhythmic risk. Our ﬁndings
support the conclusion that exercise negatively inﬂuences
cardiac structure and function in at least a proportion of
ARVD/C-associated mutation carriers.
Study limitations. Our retrospective interview–based
exercise history collection may limit interpretation of study
ﬁndings. Recall of athletic participation may have been
inaccurate in a way that varied across subpopulations (recall
bias). Additionally, participants may have deliberately
altered their responses in a way that they considered desir-
able (social desirability). We limited the inﬂuence of both by
deﬁning athletic history in broad categories (e.g., endurance
athletics participation vs. not, quartiles of average exercise
per year). Additionally, a portion of our study assessed the
risk of the development of events after clinical presentation
(Fig. 3), requiring a shorter period of recall.
Our study population also may limit ﬁndings. First,
although one third of ARVD/C patients present with
sudden death, these individuals were not included in the
study. The inﬂuence of exercise in this subpopulation may
differ. Additionally, this study only included desmosomal
mutation carriers; thus, the results may have limited impli-
cations for ARVD/C patients who do not have a desmo-
somal mutation. Likewise, we anticipate that carriers of >1
copy of a desmosomal mutation may have a worse response
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Third, those interviewed were all participants in a research
registry run by a tertiary care center, creating a potential
selection bias. Additionally, because our 87 interviewees
were members of 51 families, there was nonindependence of
observations within families. Finally, our sample size was
limited with regard to our investigation of the inﬂuence of
risk reduction after exercise reduction.
Conclusions and Clinical Recommendations
The results of this study, interpreted within the context of
previous studies, provide strong evidence demonstrating an
important link between exercise and the development and
outcomes of ARVD/C. We demonstrated for the ﬁrst time
in humans that both participation in vigorous endurance
(aerobic) athletics and greater duration of annual exercise of
all types are associated with an increased likelihood of an
ARVD/C diagnosis, ventricular arrhythmias, and HF
among a large cohort of patients with desmosomal muta-
tions. These data, combined with our 15-year experience as
a referral center for patients with ARVD/C, lead us to
conclude that restriction of frequent and endurance exercise
is important for these patients and modiﬁcation of exercise
at clinical presentation may change outcomes.
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